Lactobacillus reuteri (DSM 17938) in Infants with Functional Chronic Constipation: A Double-Blind, Randomized, Placebo-Controlled Study
Lactobacillus reuteri (DSM 17938) in Infants with Functional Chronic Constipation: A Double-Blind, Randomized, Placebo-Controlled Study
复制标题
DOI：
10.1016/j.jpeds.2010.04.066
复制
发表时间：
2010-10-01
影响因子：
5.1
通讯作者：
Staiano, Annamaria
中科院分区：
文献类型：
--
作者：
Coccorullo, Paola;Strisciuglio, Caterina;Staiano, Annamaria
目的评价罗伊氏乳杆菌的有益作用（DSM 17938）在患有功能性慢性便秘的婴儿中的应用。研究设计从2008年1月至2008年12月在44名至少6个月大的连续婴儿中进行双盲、安慰剂对照、随机研究（平均年龄+/- SD，8.2 +/- 2.4 SD;男性/女性，24/20），因功能性慢性便秘而入住那不勒斯费德里科二世大学儿科系胃肠内镜检查和运动科。将44名患有慢性便秘的婴儿随机分为2组：A组（n = 22）补充益生菌罗伊氏乳杆菌（DSM 17938），B组（n = 22）接受相同的安慰剂。主要结果指标为每周排便频率、粪便硬度和是否出现无法安慰的哭泣发作，由父母记录在每日日记中。（DSM 17938）的婴儿在第2周的排便频率显著高于接受安慰剂的婴儿（P = 0.042），第4周（P = 0.008）和第8周（P = 0.027）补充。在罗伊氏乳杆菌组中，基线时有19名婴儿（86.4%）、第2周时有11名婴儿（50%）、第4周和第8周时有4名婴儿（18.2%）报告粪便硬度。然而，在所有周，罗伊氏乳杆菌组和安慰剂组之间的粪便稠度没有显著差异（P = .63，第2周; P = .38，第4周; P = .48，第8周）。同样，两组在出现无法安慰的哭泣事件方面也没有统计学差异。没有不良反应reported.Conclusions罗伊氏乳杆菌（DSM 17938）在慢性便秘的婴儿的管理有积极的影响，肠频率，即使有改善粪便的一致性和伤心欲绝的哭泣发作。由于其安全性，益生菌可能是治疗功能性便秘的一个有吸引力的选择。（J Pediatr 2010; 157：598-602）。
Objectives To evaluate the beneficial effects of Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation.Study design A double-blind, placebo-controlled, randomized study was conducted from January 2008 to December 2008 in 44 consecutive infants at least 6 months old (mean age +/- SD, 8.2 +/- 2.4 SD; male/female, 24/20) admitted to the Gastrointestinal Endoscopy and Motility Unit of the Department of Pediatrics, University "Federico II'' of Naples, with a diagnosis of functional chronic constipation. The 44 infants with chronic constipation were randomly assigned to 2 groups: group A (n = 22) received supplementation with the probiotic L reuteri (DSM 17938) and group B (n = 22) received an identical placebo. Primary outcome measures were frequency of bowel movements per week, stool consistency, and presence of inconsolable crying episodes, recorded in a daily diary by parents.Results Infants receiving L reuteri (DSM 17938) had a significantly higher frequency of bowel movements than infants receiving a placebo at week 2 (P = .042), week 4 (P = .008), and week 8 (P = .027) of supplementation. In the L reuteri group, the stool consistency was reported as hard in 19 infants (86.4%) at baseline, in 11 infants (50%) at week 2, and in 4 infants (18.2%) at weeks 4 and 8. However, there was no significant difference between L reuteri and placebo groups in the stool consistency at all weeks (P = .63, week 2; P = .38, week 4; P = .48, week 8). Similarly, there was no statistically difference in the 2 groups in the presence of inconsolable crying episodes. No adverse effects were reported.Conclusions The administration of L reuteri (DSM 17938) in infants with chronic constipation had a positive effect on bowel frequency, even when there was no improvement in stool consistency and episodes of inconsolable crying episodes. Because of their safety profile, probiotics may be an attractive option in the treatment of functional constipation. (J Pediatr 2010; 157:598-602).